

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Jul 12 BEILSTEIN enhanced with new display and select options,
resulting in a closer connection to BABS
NEWS 4 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display
fields
NEWS 5 AUG 02 CAPLUS and CA patent records enhanced with European and Japan
Patent Office Classifications
NEWS 6 AUG 02 The Analysis Edition of STN Express with Discover!
(Version 7.01 for Windows) now available
NEWS 7 AUG 27 BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 8 AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal
status data from INPADOC
NEWS 9 SEP 01 INPADOC: New family current-awareness alert (SDI) available
NEWS 10 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 11 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 12 SEP 14 STN Patent Forum to be held October 13, 2004, in Iselin, NJ
NEWS 13 SEP 27 STANDARDS will no longer be available on STN
NEWS 14 SEP 27 SWETSCAN will no longer be available on STN
NEWS 15 SEP 30 STN downtime scheduled October 2-3, 2004

NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:11:46 ON 04 OCT 2004

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:12:00 ON 04 OCT 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 OCT 2004 HIGHEST RN 756446-64-7

DICTIONARY FILE UPDATES: 3 OCT 2004 HIGHEST RN 756446-64-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10032392.str



chain nodes :

18 20 22 23

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

chain bonds :

1-18 3-22 5-9 6-13 22-23

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-16 13-14
14-15 15-16

exact/norm bonds :

1-2 1-5 1-18 2-3 3-4 3-22 4-5 5-9 6-13 12-13 12-16 13-14 14-15 15-16
22-23

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

isolated ring systems :

containing 1 : 6 : 12 :

G1:O,S

G2:O,S

G3:O,N,X

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 20:CLASS 21:CLASS
22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

10032392.trn

10/04/2004

=> s l1

SAMPLE SEARCH INITIATED 11:12:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11 TO 389
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 11:12:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 188 TO ITERATE


100.0% PROCESSED 188 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

L3 0 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10032392a.str



chain nodes :

18 20

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

chain bonds :

1-18 5-9 6-13

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-16 13-14
14-15 15-16

exact/norm bonds :

1-2 1-5 1-18 2-3 3-4 4-5 5-9 6-13 12-13 12-16 13-14 14-15 15-16

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

isolated ring systems :

containing 1 : 6 : 12 :

G1:O,S

G2:O,S

G3:O,N,X

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 20:CLASS 21:CLASS

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 11:14:02 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 11 TO 389

PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 sss full

FULL SEARCH INITIATED 11:14:08 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 213 TO ITERATE

10032392.trn

10/04/2004


100.0% PROCESSED 213 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

L6 0 SEA SSS FUL L4

=>

Uploading C:\Program Files\Stnexp\Queries\10032392b.str



chain nodes :

18 22

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

chain bonds :

1-18 5-9 6-13 12-22

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-16 13-14
14-15 15-16

exact/norm bonds :

1-2 1-5 1-18 2-3 3-4 4-5 5-9 6-13 12-13 12-16 12-22 13-14 14-15 15-16

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

isolated ring systems :

containing 1 : 6 : 12 :

G1:O,S

G2:O,S

G3:O,N,X

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 22:CLASS

L7 STRUCTURE UPLOADED

=> d 17

L7 HAS NO ANSWERS

L7 STR



G1 O,S

G2 O,S

G3 O,N,X

Structure attributes must be viewed using STN Express query preparation.

=> s 17

SAMPLE SEARCH INITIATED 11:16:01 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 3 TO 163

PROJECTED ANSWERS: 2 TO 124

L8 2 SEA SSS SAM L7

=> FIL CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

312.94

313.15

FILE 'CAPLUS' ENTERED AT 11:16:10 ON 04 OCT 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Oct 2004 VOL 141 ISS 15
FILE LAST UPDATED: 3 Oct 2004 (20041003/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l7 sss full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 11:16:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 129 TO ITERATE

100.0% PROCESSED 129 ITERATIONS
SEARCH TIME: 00.00.01

92 ANSWERS

L9 92 SEA SSS FUL L7

L10 9 L9

=> d his

(FILE 'HOME' ENTERED AT 11:11:46 ON 04 OCT 2004)

FILE 'REGISTRY' ENTERED AT 11:12:00 ON 04 OCT 2004

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 0 S L4
L6 0 S L4 SSS FULL
L7 STRUCTURE UPLOADED
L8 2 S L7

FILE 'CAPLUS' ENTERED AT 11:16:10 ON 04 OCT 2004
S L7

FILE 'REGISTRY' ENTERED AT 11:16:20 ON 04 OCT 2004

L9 92 S L7 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:16:21 ON 04 OCT 2004

L10 9 S L9 SSS FULL

=> s l10 and py<=2000
20625355 PY<=2000

L11 6 L10 AND PY<=2000

=> d l10 ibib abs hitstr tot



L10 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:430626 CAPLUS

10/04/2004

DOCUMENT NUMBER: 141:7113
 TITLE: Preparation of novel heterocyclic compounds having antibacterial activity
 INVENTOR(S): Selvakumar, Natesan; Das, Jagattaran; Trehan, Sanjay; Iqbal, Javed; Kumar, Magadi Sitaram; Rajagopalan, Ramanujam; Rao, Mamidi Naga Venkata Srinivasa
 PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories Inc.
 SOURCE: U.S. Pat. Appl. Publ., 100 pp., Cont.-in-part of U.S. Pat. Appl. 2003 65,175.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004102494	A1	20040527	US 2003-613414	20030703
US 2003065175	A1	20030403	US 2001-32392	20011221
US 2004059120	A1	20040325	US 2003-632950	20030801
PRIORITY APPLN. INFO.:			IN 2000-MA1124	A 20001226
			IN 2001-MA15	A 20010115
			US 2001-32392	A2 20011221

OTHER SOURCE(S): MARPAT 141:7113
 GI



AB The title compds. [I; R1 = NHR4 (wherein R4 = thioacyl, C(S)cycloalkoxy, C(S)aryloxy, etc.); R2, R3 = H, halo, alkyl, etc.; Y1 = O, S; Y2, Y3 = H, halo, CN, etc.; Z = O, S, CH, CH2, (un)substituted NH], useful for inhibiting the growth of bacteria in a subject having a bacterial infection (MIC values given for some of the compds. I), were prepared E.g., a multi-step synthesis of II was given. The pharmaceutical composition comprising the compound I is claimed.


IT 439902-96-2P 439903-81-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of novel 4-(4-oxoimidazol-1-yl)phenyl substituted
oxazolidinones having antibacterial activity)

RN 439902-96-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-81-8 CAPLUS

CN Carbamothioic acid, [[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-[2-(dimethylamino)ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 439902-57-5P 439902-64-4P 439902-65-5P
439902-66-6P 439902-67-7P 439902-76-8P
439902-80-4P 439902-81-5P 439902-82-6P
439902-83-7P 439902-88-2P 439902-90-6P
439902-91-7P 439902-94-0P 439902-95-1P
439902-97-3P 439902-98-4P 439902-99-5P
439903-00-1P 439903-01-2P 439903-02-3P
439903-03-4P 439903-11-4P 439903-12-5P
439903-13-6P 439903-14-7P 439903-15-8P
439903-16-9P 439903-17-0P 439903-27-2P
439903-28-3P 439903-31-8P 439903-32-9P
439903-33-0P 439903-34-1P 439903-37-4P
439903-38-5P 439903-39-6P 439903-40-9P
439903-42-1P 439903-43-2P 439903-44-3P
439903-45-4P 439903-46-5P 439903-47-6P
439903-53-4P 439903-54-5P 439903-55-6P
439903-56-7P 439903-57-8P 439903-59-0P
439903-63-6P 439903-65-8P 439903-67-0P
439903-91-0P 439903-92-1P 439903-93-2P

439903-94-3P 439903-95-4P 439903-96-5P
439903-97-6P 439903-98-7P 439903-99-8P
439904-00-4P 439904-01-5P 439904-02-6P
439904-03-7P 439904-04-8P 693787-34-7P
693787-41-6P 693787-42-7P 693787-64-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel 4-(4-oxoimidazol-1-yl)phenyl substituted oxazolidinones having antibacterial activity)

RN 439902-57-5 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-64-4 CAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-65-5 CAPLUS

CN 2-Oxazolidinone, 3-[2-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-66-6 CAPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-67-7 CAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-76-8 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-80-4 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-81-5 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[2-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-82-6 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-83-7 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-88-2 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-90-6 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-91-7 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-94-0 CAPLUS

CN Formamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-95-1 CAPLUS

CN Formamide, N-[[[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-97-3 CAPLUS

CN Propanamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-98-4 CAPLUS

CN Butanamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-99-5 CAPLUS

CN Pentanamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-00-1 CAPLUS

CN Heptanamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-01-2 CAPLUS

CN 2-Propenamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-02-3 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-03-4 CAPLUS

CN Acetic acid, [[[5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-11-4 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-12-5 CAPLUS

CN Propanamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-13-6 CAPLUS

CN Heptanamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-14-7 CAPLUS

CN 2-Propenamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-15-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[2-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-16-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-17-0 CAPLUS

CN Propanamide, N-[[[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-27-2 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-28-3 CAPLUS

CN Propanethioamide, 3,3,3-trifluoro-N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-31-8 CAPLUS

CN Ethanethioamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-32-9 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-33-0 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-34-1 CAPLUS

CN Ethanethioamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-37-4 CAPLUS

CN Carbamic acid, [[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-38-5 CAPLUS

CN Carbamic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-39-6 CAPLUS

CN Carbamic acid, [[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-40-9 CAPLUS

CN Carbamic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-42-1 CAPLUS

CN Carbamodithioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-43-2 CAPLUS

CN Carbamodithioic acid, [[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-44-3 CAPLUS

CN Carbamodithioic acid, [[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-45-4 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-46-5 CAPLUS

CN Acetic acid, trifluoro-, anhydride with [[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]carbamothioic acid (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-47-6 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-cyclohexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-53-4 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]-, O-methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 439903-54-5 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-55-6 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-56-7 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-57-8 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-59-0 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-63-6 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-(2-hydroxyethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-65-8 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-(2-methoxyethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-67-0 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-(1-methylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-91-0 CAPLUS

CN Thiourea, N,N-diethyl-N'-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-92-1 CAPLUS

CN Thiourea, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-N'-2-propenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-93-2 CAPLUS

CN Thiourea, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-94-3 CAPLUS

CN Thiourea, N-[(4-methoxyphenyl)methyl]-N'-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-95-4 CAPLUS

CN Thiourea, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-N'-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-96-5 CAPLUS

CN Thiourea, N-methyl-N'-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-97-6 CAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-98-7 CAPLUS

CN 4-Thiomorpholinecarbothioamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-99-8 CAPLUS

CN Thiourea, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-N'-2-pyridinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439904-00-4 CAPLUS

CN Thiourea, [[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439904-01-5 CAPLUS

CN Thiourea, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439904-02-6 CAPLUS

CN Thiourea, [[[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439904-03-7 CAPLUS

CN Thiourea, N-[[[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439904-04-8 CAPLUS

CN Carbamothioic acid, [[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-[2-(dimethylamino)ethyl] ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 693787-34-7 CAPLUS

CN Propanamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 693787-41-6 CAPLUS

CN Carbamothioic acid, [[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-(2,2,2-trifluoroethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 693787-42-7 CAPLUS

CN Carbamothioic acid, [[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 693787-64-3 CAPLUS

CN 1-Pyrrolidinecarbothioamide, 2-(hydroxymethyl)-N-[[[(5S)-2-oxo-3-[4-(2-oxo-

10/04/2004

3-oxazolidinyl)phenyl]-5-oxazolidinyl)methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:5775 CAPLUS

DOCUMENT NUMBER: 138:89797

TITLE: Preparation of substituted oxazolidinones for combinational therapy in the treatment and/or prophylaxis of thromboembolic diseases

INVENTOR(S): Straub, Alexander; Lampe, Thomas; Pernerstorfer, Josef; Perzborn, Elisabeth; Pohlmann, Jens; Roehrig, Susanne; Schlemmer, Karl-Heinz

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 161 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000256	A1	20030103	WO 2002-EP6237	20020607
WO 2003000256	C2	20030206		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10129725	A1	20030102	DE 2001-10129725	20010620
EE 200400020	A	20040415	EE 2004-20	20020607
EP 1411932	A1	20040428	EP 2002-738154	20020607
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002010941	A	20040608	BR 2002-10941	20020607
PRIORITY APPLN. INFO.:			DE 2001-10129725	A 20010620
			WO 2002-EP6237	W 20020607
OTHER SOURCE(S):	MARPAT 138:89797			

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to combinations of (A) oxazolidinones I [R1 = 5-X-2-thienyl (X = Cl, Br, Me, CF₃); R2 = DA; A = phenylene; D = 5- or 6-membered heterocyclic ring containing S, N or O; R4 - R8 = H], or their pharmaceutically acceptable salts, hydrates, prodrugs or their mixts. and (B) other pharmaceutically active ingredients; to a method for producing said combinations; and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases. Thus, the claimed oxazalone II was prepared from epoxide III via epoxide ring opening with aniline derivative IV, cyclization with carbonyldiimidazole, and N-acylation with 5-chlorothiophene-2-sulfonyl chloride. II was tested for antithrombotic activity in the arteriovenous shunt model (Rat) after [ED50 = 3 mg/kg (p.o.); IC50 = 0.7 nM]; II had a synergistic effect when used in combination with clopidogrel.

IT 482305-90-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and pharmacol. activity of; preparation of substituted oxazolidinones for combinational therapy in the treatment and/or prophylaxis of thromboembolic diseases)

RN 482305-90-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:504766 CAPLUS

DOCUMENT NUMBER: 137:78944



TITLE:

INVENTOR(S):

Preparation of aryl oxazolones as antibacterials.
Natesan, Selvakumar; Das, Jagattaran; Iqbal, Javed;
Magadi, Sridhar Kumar; Mamidi, Naga Venkata Srinivasa
Rao; Ramanujam, Rajagopalan; Sundarababu, Baskaran;
Lohray, Braj Bhushan
Dr. Reddy's Research Foundation, India; Dr. Reddy's
Laboratories Ltd.

SOURCE: PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051819	A2	20020704	WO 2001-IN227	20011226
WO 2002051819	A3	20021205		
WO 2002051819	C2	20030807		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1345913	A2	20030924	EP 2001-995805	20011226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300254	A	20031215	EE 2003-254	20011226
BR 2001016571	A	20040302	BR 2001-16571	20011226
JP 2004525876	T2	20040826	JP 2002-552914	20011226
NO 2003002926	A	20030825	NO 2003-2926	20030625
PRIORITY APPLN. INFO.:				
			IN 2000-MA1124	A 20001226
			IN 2001-MA15	A 20010115
			WO 2001-IN227	W 20011226
OTHER SOURCE(S): MARPAT 137:78944				
GI				



AB Title compds. [I; R1 = halo, N3, SCN, SH, OR4, NHR4, N(R4)2; R4 = H, (substituted) acyl, thioacyl, alkoxycarbonyl, cycloalkoxythiocarbonyl, alkenyloxycarbonyl, alkenylcarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, alkenyloxythiocarbonyl, aryloxythiocarbonyl, COCOA, COCOAr, COCOalk, COCOArO, CS2A, CSNH2, CSNHA, CSNA2, CSNHak, CSCOalk, CSCOArO, CSO2CA, CSCSA, CSCSAr, thiomorpholinylthiocarbonyl, pyrrolidinylthiocarbonyl; A =

alkyl; Ar = aryl; Alk = alkoxy; Ak = alkenyl; R2, R3 = H, halo, alkyl, haloalkyl, cyano, nitro, SRa, NRA, ORa; Ra = (substituted) alkyl, haloalkyl; Z = S, O, CH, NRB; Rb = H, (substituted) alkyl, alkenyl, cycloalkyl, alkoxy, aryl, aralkyl, aryloxy, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxy carbonyl; Y1 = O, S; Y2, Y3 = H, halo, cyano, NO2, formyl, OH, amino, O, S, (substituted) alkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino, alkoxy, aryl, aryloxy, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl heterocycloalkyl; adjacent Y2Y3 form a (substituted) 5-6 membered aromatic or nonarom. cyclic structure, optionally containing 1-2 heteroatoms], were prepared. Thus, title compound (II) (general preparation given) showed a min. inhibitory concentration of 0.25 µg/mL

against

Staphylococcus aureus 019 MRSA.

IT 439902-57-5P 439902-64-4P 439902-65-5P
 439902-66-6P 439902-67-7P 439902-76-8P
 439902-80-4P 439902-81-5P 439902-82-6P
 439902-83-7P 439902-88-2P 439902-90-6P
 439902-91-7P 439902-94-0P 439902-95-1P
 439902-96-2P 439902-97-3P 439902-98-4P
 439902-99-5P 439903-00-1P 439903-01-2P
 439903-02-3P 439903-03-4P 439903-11-4P
 439903-12-5P 439903-13-6P 439903-14-7P
 439903-15-8P 439903-16-9P 439903-17-0P
 439903-18-1P 439903-27-2P 439903-28-3P
 439903-31-8P 439903-32-9P 439903-33-0P
 439903-34-1P 439903-37-4P 439903-38-5P
 439903-39-6P 439903-40-9P 439903-42-1P
 439903-43-2P 439903-44-3P 439903-45-4P
 439903-46-5P 439903-47-6P 439903-53-4P
 439903-54-5P 439903-55-6P 439903-56-7P
 439903-57-8P 439903-59-0P 439903-61-4P
 439903-63-6P 439903-65-8P 439903-66-9P
 439903-67-0P 439903-81-8P 439903-90-9P
 439903-91-0P 439903-92-1P 439903-93-2P
 439903-94-3P 439903-95-4P 439903-96-5P
 439903-97-6P 439903-98-7P 439903-99-8P
 439904-00-4P 439904-01-5P 439904-02-6P
 439904-03-7P 439904-04-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryloxazolones as antibacterials)

RN 439902-57-5 CAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-64-4 CAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-65-5 CAPLUS

CN 2-Oxazolidinone, 3-[2-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-66-6 CAPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-67-7 CAPLUS

CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-76-8 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-80-4 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-81-5 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[2-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-82-6 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-83-7 CAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-88-2 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-90-6 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-91-7 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-94-0 CAPLUS

CN Formamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-95-1 CAPLUS

CN Formamide, N-[[[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-96-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-97-3 CAPLUS

CN Propanamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-98-4 CAPLUS

CN Butanamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-99-5 CAPLUS

CN Pentanamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-00-1 CAPLUS

CN Heptanamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-01-2 CAPLUS

CN 2-Propenamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-02-3 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-03-4 CAPLUS

CN Acetic acid, [[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-11-4 CAPLUS

CN Acetamide, N-[[[5S]-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-12-5 CAPLUS

CN Propanamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-13-6 CAPLUS

CN Heptanamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-14-7 CAPLUS

CN 2-Propenamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-15-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[2-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-16-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-17-0 CAPLUS

CN Propanamide, N-[[[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-18-1 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-27-2 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-28-3 CAPLUS

CN Propanethioamide, 3,3,3-trifluoro-N-[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-31-8 CAPLUS

CN Ethanethioamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-32-9 CAPLUS

CN Ethanethioamide, N-[[(5S) -3- [3,5-difluoro-4- (2-oxo-3-oxazolidinyl)phenyl] -2-oxo-5-oxazolidinyl]methyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-33-0 CAPLUS

CN Propanethioamide, N-[[[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-34-1 CAPLUS

CN Ethanethioamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-37-4 CAPLUS

CN Carbamic acid, [[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-38-5 CAPLUS

CN Carbamic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-39-6 CAPLUS

CN Carbamic acid, [[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-40-9 CAPLUS

CN Carbamic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-42-1 CAPLUS

CN Carbamodithioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-43-2 CAPLUS

CN Carbamodithioic acid, [[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-44-3 CAPLUS

CN Carbamodithioic acid, [[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-45-4 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-46-5 CAPLUS

CN Acetic acid, trifluoro-, anhydride with [[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]carbamothioic acid (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-47-6 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-cyclohexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-53-4 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]-, O-methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 439903-54-5 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)-3-(trifluoromethyl)phenyl]-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-55-6 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-56-7 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-57-8 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-59-0 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-61-4 CAPLUS

CN Propanethioamide, 3,3,3-trifluoro-N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-63-6 CAPLUS

CN Carbamothioic acid, [[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl)methyl]-, O-(2-hydroxyethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-65-8 CAPLUS

CN Carbamothioic acid, [[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl)methyl]-, O-(2-methoxyethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-66-9 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-ethenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-67-0 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-(1-methylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-81-8 CAPLUS

CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-[2-(dimethylamino)ethyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-90-9 CAPLUS

CN 1-Pyrrolidinecarbothioamide, 2-(hydroxymethyl)-N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-91-0 CAPLUS

CN Thiourea, N,N-diethyl-N'-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-92-1 CAPLUS

CN Thiourea, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-N'-2-propenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-93-2 CAPLUS

CN Thiourea, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-94-3 CAPLUS

CN Thiourea, N-[[[(4-methoxyphenyl)methyl]-N'-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-95-4 CAPLUS

CN Thiourea, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-N'-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-96-5 CAPLUS

CN Thiourea, N-methyl-N'-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-97-6 CAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-98-7 CAPLUS

CN 4-Thiomorpholinecarbothioamide, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-99-8 CAPLUS

CN Thiourea, N-[[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-N'-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439904-00-4 CAPLUS

CN Thiourea, [[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439904-01-5 CAPLUS

CN Thiourea, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439904-02-6 CAPLUS

CN Thiourea, [[[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439904-03-7 CAPLUS

CN Thiourea, N-[[[(5S)-3-[3,5-difluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439904-04-8 CAPLUS

CN Carbamothioic acid, [[[(5S)-2-oxo-3-[4-(2-oxo-3-oxazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-[2-(dimethylamino)ethyl] ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L10 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1979:421173 CAPLUS

DOCUMENT NUMBER: 91:21173

TITLE: Poly-2-oxazolidinones prepared from isocyanates and epoxides

AUTHOR(S): Braun, Dietrich; Weinert, Johann

CORPORATE SOURCE: Dtsch. Kunstst. Inst., Darmstadt, 6100, Fed. Rep. Ger.

SOURCE: Angewandte Makromolekulare Chemie (1979), 78, 1-19

CODEN: ANMCBO; ISSN: 0003-3146

DOCUMENT TYPE: Journal

LANGUAGE: German

AB Diisocyanates [OCNZNCO; Z = (CH₂)₆, p-C₆H₄, 2,6-tolylene] are copolymd. in polar organic solvents with bisphenol A and hydroquinone diglycidyl ethers, p-phenylenedioxirane, and hexamethylenedioxirane to give polymers containing 2-oxazolidinone units and stable to 250-340°C. ONC(CH₂)₆NCO with aromatic dioxiranes yields products m. 80-100° and soluble in DMF, while aromatic diisocyanates provide polymers m. 210-30° plus dark, infusible byproducts, the formation of which may be avoided by using low-melting monooxazolidinones as solvents.


IT 70649-98-8P 70649-99-9P 70650-00-9P
70656-56-3P


RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and thermal properties of)

RN 70649-98-8 CAPLUS

CN Poly[(2-oxo-5,3-oxazolidinediyl)-1,4-phenylene(2-oxo-3,5-oxazolidinediyl)methyleneoxy-1,4-phenylene(1-methylethylidene)-1,4-phenyleneoxymethylene] (9CI) (CA INDEX NAME)


PAGE 1-A






RN 70649-99-9 CAPLUS

CN Poly[(2-oxo-5,3-oxazolidinediyl)-1,4-phenylene(2-oxo-3,5-oxazolidinediyl)methyleneoxy-1,4-phenyleneoxymethylene] (9CI) (CA INDEX NAME)




RN 70650-00-9 CAPLUS

CN Poly[(2-oxo-5,3-oxazolidinediyl)-1,4-phenylene(2-oxo-3,5-oxazolidinediyl)-1,4-phenylene] (9CI) (CA INDEX NAME)



RN 70656-56-3 CAPLUS

CN Poly[(2-oxo-5,3-oxazolidinediyl)-1,4-phenylene(2-oxo-3,5-oxazolidinediyl)-1,6-hexanediyl] (9CI) (CA INDEX NAME)




IT 69974-32-9 69974-33-0

RL: PRP (Properties)
(thermal stability of)


RN 69974-32-9 CAPLUS

CN 2-Oxazolidinone, 3,3'-(1,4-phenylene)bis[5-phenyl- (9CI) (CA INDEX NAME)



RN 69974-33-0 CAPLUS

CN 2-Oxazolidinone, 3,3'-(1,4-phenylene)bis[4-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1979:168494 CAPLUS

DOCUMENT NUMBER: 90:168494

TITLE: Reaction of epoxides with isocyanates, II.

Preparation and characterization of 2-oxazolidinones

AUTHOR(S): Braun, Dietrich; Weinert, Johann

CORPORATE SOURCE: Dtsch. Kunstst.-Inst., Darmstadt, Fed. Rep. Ger.

SOURCE: Liebigs Annalen der Chemie (1979), (2), 200-9


CODEN: LACHDL; ISSN: 0170-2041

DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 90:168494

GI



AB Isocyanates react with epoxides to yield 2-oxazolidinones. The reaction of isocyanates with unsym. substituted epoxides I (R = Me, Ph, vinyl) was studied in order to investigate differences in the direction of ring opening of the epoxides as a function of the type of catalyst (nucleophilic or electrophilic). With the exception of I (R = Ph), where 3,4-diphenyl-2-oxazolidinone and 3,3'-p-phenylenebis(4-phenyl-2-oxazolidinone) are formed, epoxides lead to 5-substituted 2-oxazolidinones, independent of the catalyst.


IT 69974-32-9P 69974-33-0P 69974-34-1P

10/04/2004

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 69974-32-9 CAPLUS

CN 2-Oxazolidinone, 3,3'-(1,4-phenylene)bis[5-phenyl- (9CI) (CA INDEX NAME)




RN 69974-33-0 CAPLUS

CN 2-Oxazolidinone, 3,3'-(1,4-phenylene)bis[4-phenyl- (9CI) (CA INDEX NAME)



RN 69974-34-1 CAPLUS

CN 2-Oxazolidinone, 3,3'-(1,4-phenylene)bis[4-(hydroxymethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1979:167509 CAPLUS

DOCUMENT NUMBER: 90:167509

TITLE: Reaction of epoxides with isocyanates, III. Study of 2-oxazolidinones by mass spectrometry

AUTHOR(S): Braun, Dietrich; Weinert, Johann

CORPORATE SOURCE: Dtsch. Kunstst.-Inst., Darmstadt, Fed. Rep. Ger.

SOURCE: Liebigs Annalen der Chemie (1979), (2), 210-18

CODEN: LACHDL; ISSN: 0170-2041

DOCUMENT TYPE: Journal

LANGUAGE: German

AB The decomposition of 2-oxazolidinones in the mass spectrometer is initiated by elimination of CO₂ by β -decomposition and α -cleavage by liberation


of CO and of the corresponding aldehyde. The 5-aryl-3-phenyl-2-oxazolidinones undergo both reactions at roughly equal rates. 5-Alkyl- or 5-alkylidene-3-phenyl-2-oxazolidinones preferentially eliminate CO₂. The main degradation reaction of 4-aryl-3-phenyl-2-oxazolidinones is α -cleavage.

IT 69974-21-6 69974-22-7 69974-29-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(mass spectral decomposition of)


RN 69974-21-6 CAPLUS

CN 2-Oxazolidinone, 3,3'-(1,4-phenylene)bis[5-phenyl-, radical ion(1+) (9CI)
(CA INDEX NAME)




RN 69974-22-7 CAPLUS

CN 2-Oxazolidinone, 3,3'-(1,4-phenylene)bis[4-phenyl-, radical ion(1+) (9CI)
(CA INDEX NAME)



RN 69974-29-4 CAPLUS

CN 2-Oxazolidinone, 3,3'-(1,4-phenylene)bis[4-(hydroxymethyl)-, conjugate monoacid (9CI) (CA INDEX NAME)



● H⁺


ACCESSION NUMBER: 1968:467922 CAPLUS
 DOCUMENT NUMBER: 69:67922
 TITLE: Poly(2,4-oxazolidinediones)
 INVENTOR(S): Maekawa, Haruki; Harada, Kimiko
 PATENT ASSIGNEE(S): Toyo Rayon Co., Ltd.
 SOURCE: Jpn. Tokkyo Koho, 5 pp.
 CODEN: JAXXAD
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 43009077	B4	19680412	JP	19641209

AB α, α' -Dihydroxydicarboxylic esters such as p-[MeO2CCH(OH)]2C6H4 (I), [p-MeO2CCH(OH)C6H4]2, and 1,3-cyclohexylene bisglycolate esters are treated with an organic diisocyanate at <150° to give a polyurethane which was pyrolyzed to give the heat-stable title polymers. Thus, 10.1 g. I and 10 g. (p-OCNC6H4)2CH2 in 50 ml. warm Cl2CHCHCl2 were treated with 0.05 g. Bu2Sn dilaurate to give a rubberlike polymer, which was taken up in HCONMe2 and made into colorless film, m. 195-200°. Heating 10 hrs. at 200° gave a yellow, flexible film, m. >300°, resistant 15 hrs. to 65% H2SO4 at 100°. 1,4-Cyclohexylene diisocyanate and p-(OCN)2C6H4 were also used.

IT 31761-47-4P
 RL: PREP (Preparation)
 (preparation of)

RN 31761-47-4 CAPLUS
 CN Poly[(2,4-dioxo-3,5-oxazolidinediyl)-1,3-cyclohexanediyl(2,4-dioxo-5,3-oxazolidinediyl)-1,4-phenylene] (9CI) (CA INDEX NAME)



L10 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1962:469211 CAPLUS
 DOCUMENT NUMBER: 57:69211
 ORIGINAL REFERENCE NO.: 57:13748f-i,13749a-b
 TITLE: Studies of 2-oxazolidinones. I. A convenient synthesis of 3-substituted 2-oxazolidinones
 AUTHOR(S): Oda, Ryohei; Miyanoki, Masahiko; Okano, Masaya
 CORPORATE SOURCE: Kyoto Univ., Sakyo-ku
 SOURCE: Bulletin of the Chemical Society of Japan (1962), 35, 1309-12
 CODEN: BCSJA8; ISSN: 0009-2673
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable


AB RR'NCO2CH2CH2Cl (I) was prepared (Method A) by the condensation of -chloroethyl chloroformate (II) with amines and (Method B) by that of

isocyanates with ethylene chlorohydrin (III). I was then cyclized to 3-substituted 2-oxazolidinone by the use of NaOEt. COCl₂ passed rapidly into 161 g. III 3 hrs. at 0°, allowed to stand until the evolution of HCl had subsided, refluxed 2 hrs., and distilled gave 93% II, b. 149-53°. II (59 g.) added to a mixture of 25 g. tert-BuNH₂ and 41 g. Et₃N, heated to 70° 30 min., poured onto 200 ml. H₂O, extracted with two 100-ml. portions ET₂O, dried, and distilled yielded 63% I (R = tert-Bu), b. 70°. A mixture of 43 g. II and 34.5 g. o-nitroaniline heated to 120° 1 hr. yielded 98% I (R = o-nitrophenyl), m. 70.5° (ligroine). A mixture of 25 g. nBuNCO and 21 g. III in 50 ml. dry benzene refluxed 5 hrs., concentrated, and distilled yielded 83% I (R = Bu), b. 4.3 113°. III (21 g.) and 33.3 g. p-tolylisocyanate in 50 ml. toluene refluxed 2 hrs. and evaporated gave 78% I (R = p-tolyl), m. 61° (benzene). I prepared were (R, R', method of preparation, % yield, and m.p. given): Ph, H, B, 80, 49°; o-tolyl, H, A, 91, 45°; p-NO₂C₆H₄, H, B, 88, 116°; p-EtO₂CC₆H₄, H, A, 86, 145°; p-ClC₆H₄, H, A, 69, 69°; 1-anthraquinonyl, H, A, 84, 184°; (RR'=) (CH₂)₂, A, 39, 136°; (RR'=) (CH₂)₄, B, 50, 118°. Also prepared were (ClCH₂CH₂O₂CNH) ₂ C₆H₄-m, B, 79, 115.5° and (ClCH₂CH₂O₂CNH) ₂ C₆H₄-p, B, 78, 202°. NaOEt prepared from 7.5 g. Na and 50 ml. EtOH was added to 48.5 g. I [(RR'=) (CH₂)₄] in 50 ml. dioxane at 70-80°, heated 1 hr., filtered to remove NaCl, and the solvent evaporated to give 95% 3,3'-tetramethylenebis(2-oxazolidinone), m. 118°. A solution of 5g. Na in 50ml. EtOH added to 29.5 g. I (R = Ph, R' = H) in 50 ml. EtOH at 65-70° and heated 1 hr. yielded 94% 3-phenyl-2-oxazolidinone, m. 118.0 (benzene). 3-R-2-Oxazolidinones prepared were [R, % yield, m.p. (or b.p.) given]: Bu, 80, (b. 122°); tert-Bu, 62, (b. 94°); p-tolyl, 70, 91°; o-tolyl, 80, (b. 170°); p-O₂NC₆H₄, 95, 154.5°; o-O₂NC₆H₄, 94, 165°; EtO₂CC₆H₄, 97, 110°; p-ClC₆H₄, 85, 121°; 1-anthraquinonyl, 85, 226.5°. Also prepared were: 3,3'-ethylenebis(2-oxazolidinone), 80, 107°; 3,3'-m-phenylenebis(2-oxazolidinone), 62, 175°; 3,3'-p-phenylenebis(2-oxazolidinone), 68, 253°.

IT 92848-70-9, 2-Oxazolidinone, 3,3'-p-phenylenebis-
(preparation of)

RN 92848-70-9 CAPLUS

CN 2-Oxazolidinone, 3,3'-p-phenylenebis- (7CI) (CA INDEX NAME)



L10 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1957:29820 CAPLUS

DOCUMENT NUMBER: 51:29820

ORIGINAL REFERENCE NO.: 51:5754g-i,5755a-i,5756a-c

TITLE: The azole series. I. Preparation and properties of 2-oxazolones

AUTHOR(S): Gompper, Rudolf

CORPORATE SOURCE: Tech. Hochschule, Stuttgart, Germany

SOURCE: Chemische Berichte (1956), 89, 1748-62

CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal


LANGUAGE: Unavailable

AB Refluxing 10 g. benzoin with 25 g. Me₂NCOC₂H₅ 4 hrs. on a water bath and distilling the chloride yield 90% benzoin N,N-dimethylcarbamate (I), m. 156°. Treating 37 g. PhCOCH₂NHCO₂Et with 4.5 g. Na in EtOH 15 hrs. at 20° and adding H₂O give α-carbethoxyamino-N-phenacylbenzoylacetamide (II), m. 286° (decomposition). N-Unsubstituted 2-oxazolones are prepared: a, by heating an α-hydroxyketone (III) with excess urethan (IV) in a ratio of 1:5-10 with slow distillation and pouring the mixture into H₂O; b, by refluxing III with excess IV in HCONMe₂ in the presence of a small amount of C₅H₅N; c, by refluxing III and IV in AcOH in the presence of concentrated H₂SO₄; da, by adding a carbamide acid chloride and C₅H₅N to III in C₆H₆ or Et₂O with cooling, keeping the mixture several hrs. at 20°, distilling the solvent, and refluxing the residue 1 hr. with 5:1 EtOH-H₂SO₄; db, treating the mixture without removal of the solvent 2-4 hrs. with polyphosphoric acid, pouring the mixture into H₂O, and making the solution alkaline with NaOH; e, heating a N,N-dimethylcarbamide acid ester of

III with a mixture of NH₄OAc and AcOH. Refluxing 33 g. propionoin (V) and 81 g. IV 15 hrs. in 70 cc. HCONMe₂ gives 37% 4,5-diethyl-2-oxazolone, b0.01 135-6°, m. 73°, which is also obtained in 40% yield when 38.7 g. V and 27 g. H₂NCOC₂H₅ in 500 cc. C₆H₆ are kept at 20°, the mixture is poured into H₂O, adjusted to pH 8, extracted with Et₂O, and the residue of the Et₂O is fractionally distilled. Treating 28 g. butyroin and 174 g. IV 6 hrs. according to a yields 41% 4,5-dipropyl-2-oxazolone (VI), b0.05 150°, m. 220°; according to b (15 hrs. reflux), 46% VI; or according to d, from 53 g. butyroin and 44 g. H₂NCOC₂H₅ in 400 cc. C₆H₆, 71% VI. 4,5-Diisopropyl-2-oxazolone, b, from 29 g. isobutyroin (VII) and 80 g. IV in 100 cc. HCONMe₂, 46%, b0.02 128-33°, platelets, m. 128°; da, from 18.5 g. VII and 10.3 g. H₂NCOC₂H₅ in 350 cc. C₆H₆, 58%, m. 136°. The following addnl. substituted 2-oxazolones are prepared: 4,5-di-Bu, da, 47%, b0.01 166-7°; 4,5-di-Me₂CHCH₂, da, 64%, b0.2 172-4°; 4,5-di-Am, da, 17%, b0.02 160-2°; 4,5-di-C₆H₁₃, da, 19%, b0.02 162°; 4,5-di-C₇H₁₅, da, 50%, b0.005 167°; 4,5-di-C₉H₁₉, da, 41%, b0.02 220-2°; 5-Et, 4-Ph, da, 49%, b0.005 134-44°, m. 128°; 5-Pr homolog, da, 94%, b0.01 180-5°, m. 135°; 5-Bu homolog, db, 41% b0.01 186°; 5-C₈H₁₇ homolog, db, 44%, b0.01 193°; 4,5-di-Ph (VIII), a, 91%, b (6 hrs.), 93%, c (3 hrs.), 51%, da, 84%, e (6 hrs.), 95%, shiny needles, m. 211°; 5-phenyl-4-(p-methoxyphenyl), da, 71%, m. 212°; 4,5-bis(3,4,5-trimethoxyphenyl), b (5 hrs.), 75%, m. 214-15°; 4,5-bis(p-chlorophenyl), b (8 hrs.), 57%, m. 195°; 5-phenyl-4-(p-dimethylaminophenyl) (IX), from 75 g. p-dimethylaminobenzoin (X) and 15 g. IV, a (5 hrs.), 42%, m. 205° (decomposition); p-di-Et homolog, from 8.5 g. p-diethylaminobenzoin and 21 g. IV, a, 43%, m. 208° (decomposition); 3,5-di-(2-pyridyl), from 11 g. α-pyridoin and 22 g. IV, b (16 hrs.), 41%, shiny deep red needles, m. 219°; 4,5-tetramethylene-2-imidazolone, from 20 g. cyclohexanolone and 90 g. IV, b (30 hrs.), 46%, m. 346°. Methylation of 9 (or 9.6) g. VI in 100 cc. MeOH with CH₂N₂ (or in aqueous Me₂CO at pH 8-9 with Me₂SO₄) yields 51% (or 68%) 3-methyl-VI, b0.01 110-14°; methylation of 11 (or 5) g. VIII (or 4 g. acetyl-VIII) in 300 cc. N NaOH and Me₂CO (or in 20 or 50 cc. MeOH) with 19 g. Me₂SO₄ and 100 cc. N NaOH (or excess CH₂N₂) at 40° and 2 hrs. at 100° gives 90% (94 or 78%) 3-methyl-VIII, b0.04 195-215°, needles, m. 96°. Refluxing 5 g. VIII and 6 g. Ag₂O 8 hrs. in 12 g. MeI gives 62% 2-methoxy-VIII, b0.01 125-42°, and 0.9 g. 3-methyl-VIII, b0.01 160-72°. Adding 12 g. PhCH₂Cl dropwise to 9 g. VIII in 100 cc. N NaOH and 100 cc. Me₂CO at 40-50° with stirring, keeping the mixture 3 hrs., diluting it with H₂O, and extracting with Et₂O give 41% 3-benzyl-VIII, m. 100°. Refluxing 30 g. VI 3 hrs.

with 14 g. C₅H₅N and 150 cc. Ac₂O yields 64% 4,5-dipropyl-3-acetyl-2-oxazolone, b_{0.02} 86-7°, b_{0.002} 70°; 3-acetyl-VIII, 85%, m. 139°, is readily saponified on treatment with NH₄OH; 3-chloroacetyl-VIII, 91%, m. 155°; 3-benzoyl-VIII, 67%, m. 178°; 3-acetyl-IX, 55%, needles, m. 147°. Treating 23 g. V with 23 g. PhNCO and a few drops of C₅H₅N gave 42% propionoin carbanilate, m. 121°, which (13.7 g.), refluxed with 80 cc. Ac₂O, yields 64% 4,5-diethyl-3-phenyl-2-oxazolone, m. 96.5°; butyroin carbanilate, 67%, m. 132°; 4,5-dipropyl-3-phenyl-2-oxazolone, 84%, m. 50.5°. Warming 10 g. butyroin and 10 g. PhCH₂NCO with a few drops of C₅H₅N 2 hrs. on a water bath gives 88% butyroin N-benzylcarbamate, m. 133-4°; 4,5-dipropyl-3-benzyl-2-oxazolone b_{0.001} 148-56°, m. about 40°. Refluxing 57.5 g. butyroin, 35.2 g. p-C₆H₄(NCO)₂, and 1 cc. C₅H₅N 4 hrs. in 140 cc. C₆H₆ yields 81% N,N'-p-phenylenebis(carbamidoacid butyroin ester), m. 181°, which (54 g.), refluxed 2 hrs. with 300 cc. EtOH and 50 cc. concentrated H₂SO₄, gives 91% 1,4-bis(4,5-dipropyl-2-oxazolone-3-yl)benzene, m. 132°. Refluxing 34.5 g. valeroin (XI), 27.5 g. C₆H₁₁NCO, and 1 cc. C₅H₅N 6 hrs. in 100 cc. C₆H₆, distilling the C₆H₆, and refluxing the residue 1 hr. in 200 cc. EtOH and 50 cc. concentrated H₂SO₄ yield 40% 4,5-dibutyl-3-cyclohexyl-2-oxazolone, b_{0.01} 115-19°; similarly, 34 g. XI, 24 g. PhNCO, and some C₅H₅N 1 day at 20° and 1 hr. at 100° give 46% 4,5-dibutyl-3-phenyl-2-oxazolone, b_{0.005} 142-6°. Refluxing 50 g. PhCOCH(OH)Et, 58 g. PhNCO, and 1 cc. C₅H₅N in 100 cc. C₆H₆ 3 hrs. gives 50% α-hydroxybutyrophenone carbanilate, fine silky needles, m. 164°, which (41 g.), refluxed 3 hrs. in 160 g. AcOH, gives 91% 5-ethyl-3,4-diphenyl-2-oxazolone, cubes, m. 121°. Benzoin and PhNCO via the benzoin carbanilate yield 90% 3,4,5-triphenyl-2-oxazolone, m. 211°, which is also obtained in 76% yield when 15 g. benzoin, 57 g. PhNHCO₂Et, and 2 cc. C₅H₅N in 150 cc. HCONMe₂ are refluxed 12 hrs., or in 10% yield when 14 g. BzCl is added dropwise to 7 g. NaN₃ in 150 cc. HCONMe₂, then 20 g. benzoin and 0.5 cc. C₅H₅N added, and the mixt heated 2 hrs. at 50°. Heating 10 g. benzoin and 6.6 g PhCH₂NCO 0.5 hr. at 110-20° yields 50% benzoin N-benzylcarbamate, m. 188°, which (6.6 g.), refluxed 2 hrs. in 150 cc. AcOH, gives 83% 3-benzyl-VIII, m. 100°. Refluxing 7 g. benzoin and 35 g. 2-C₁₀H₇NHCO₂Et in 100 cc. HCONMe₂ 20 hrs. yields 52% 4,5-diphenyl-3-β-naphthyl-2-oxazolone, m. 195-6°. Refluxing 20 g. p-methoxybenzoin and 12 g. PhNCO 2 hrs. in 150 cc. C₆H₆ gives 97% p-methoxybenzoin carbanilate, m. 209°, which (16 g.) refluxed 2 hrs. with 150 cc. EtOH and 30 cc. concentrated H₂SO₄, gives 85% 3,5-diphenyl-4-(p-methoxyphenyl)-2-oxazolone, m. 161°. Refluxing 23 g. X and 21 g. PhNCO 1 hr. in 150 cc. C₆H₆ gives 91% p-dimethylaminobenzoin carbanilate, m. 211°, which (16 g.), refluxed in EtOH and concentrated H₂SO₄, yields 85% 3,5-diphenyl-4-(p-dimethylaminophenyl)-2-oxazolone, m. 245°. Refluxing 169 g. PhCOCHBrEt 12 hrs. in 133 g. H₂O and 375 g. HCONMe₂ gives 75% PhCOCH(OH)Et, b₁₂ 131.5-2.5°; PhCOCHBrPr, refluxed 20 hrs. in 250 cc. HCONMe₂ and 90 g. H₂O, gives 80% PhCOCH(OH)Pr, b_{0.05} 80°; PhCOCH(OH)Bu, 67%, b_{0.01} 84°; PhCOCH(OH)C₈H₁₇, 78%, b_{0.01} 115°.

IT 113927-66-5, 4-Oxazolin-2-one, 3,3'-p-phenylenebis[4,5-dipropyl-
(preparation of)
RN 113927-66-5 CAPLUS
CN 4-Oxazolin-2-one, 3,3'-p-phenylenebis[4,5-dipropyl- (6CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
46.42	515.43

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-6.30	-6.30

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 11:18:35 ON 04 OCT 2004